Journal
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
Volume 113, Issue 3, Pages 234-243Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/djaa064
Keywords
-
Categories
Funding
- Dana-Farber/Harvard Cancer Center Kidney Cancer program
- Kidney SPORE [P50CA101942-12]
- National Cancer Institute
- Department of Defense
- Trust Family
- Loker Pinard Funds for Kidney Cancer Research at Dana-Farber Cancer Institute
- Jerome and Nancy Kohlberg Chair at Harvard Medical School
- Burroughs Wellcome Fund Career Award at the Scientific Interface
- NIH Director's New Innovator Award [DP2 TR002776]
- American Cancer Society [129784IRG-16-188-38-IRG]
- Abramson Cancer Center School of Engineering and Applied Sciences Discovery Grant [P30 CA016520]
- 2018 AACR-Bayer Innovation and Discovery Grant [18-80-44-MITC]
- NATIONAL CANCER INSTITUTE [ZIDBC011089, ZIABC011028, ZIABC011038, ZIABC011043] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Kidney cancer is a common form of cancer, and the Kidney Cancer Research Summit (KCRS) was launched to promote collaboration and therapeutic advances. The conference covered topics such as tumor microenvironment, drug delivery methods, single cell sequencing, immunotherapy, predictive biomarkers, and rare variants of kidney cancers.
Kidney cancer is one of the 10 most common cancers both in the United States and worldwide. Until this year, there had not previously been a conference focused on translational studies in the broad and heterogeneous group of kidney cancers. Therefore, a group of researchers, clinicians, and patient advocates dedicated to renal cell carcinoma launched the Kidney Cancer Research Summit (KCRS) to spur collaboration and further therapeutic advances in these tumors. This commentary aims to summarize the oral presentations and serve as a record for future iterations of this meeting. The KCRS sessions addressed the tumor microenvironment, novel methods of drug delivery, single cell sequencing strategies, novel immune checkpoint blockade and cellular therapies, predictive biomarkers, and rare variants of kidney cancers. In addition, the meeting included 2 sessions to promote scientific mentoring and kidney cancer research collaborations. A subsequent KCRS will be planned for the fall of 2020.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available